ACE ASC01 Subcontract Fully Executed

Research Trial for patients with Scleroderma (SSc) and pulmonary arterial hypertension (PAH)

The Division of Pulmonary & Critical Care Medicine at Thomas Jefferson University Hospital is one of the US sites participating in a Research Trial for patients with Scleroderma (SSc) and pulmonary arterial hypertension (PAH). 
The primary purpose of this study is to evaluate the safety and tolerability of rituximab for the treatment of SSc-PAH, while evaluating the drug's effect on PAH.  The use of rituximab for the treatment of SSc-PAH in this research study is investigational. 
For more information please call one of the following:
Elizabeth Grace, Study Coordinator

Elizabeth Grace, Study Coordinator
215-955-5778 or 215-990-6677
email at elizabeth.grace@jefferson.edu
Sandra Weibel, M.D., Principal Investigator
215-955-6591
sandra.weibel@jefferson.edu
Sergio Jimenez, M.D., Co-Investigator
215-955-6680
sergio.jimenez@jefferson.edu
Michael Scharf, M.D., Co-Investigator
215-955-6591
michael.scharf@jefferson.edu
Fabian A. Mendoza-Ballesteros, M.D., Co-Investigator
215-955-8430
fabian.mendozaballesteros@jefferson.edu
 

Published: 10-21-2011

Close Window